Jing Bo is currently an evaluator for the Pharmaceutical Benefits Advisory Committee (PBAC). She is one of the few professionals in Australia with experience across three sectors of the drug reimbursement cycle, from industry consulting, evaluation and government, in addition to having solid clinical skills from training as a hospital pharmacist. She is also experienced in critically appraising economic evaluations for the Agency for Care Effectiveness (Singapore Government), and writing submissions to the PBAC on behalf of pharmaceutical companies.
Previously, Jing Bo was an Assistant Director in the Australian Government Department of Health. In that role, Jing Bo provided technical support to the PBAC and the Economics Sub-Committee (ESC). Jing Bo also worked closely with the Medical Services Advisory Committee (MSAC) teams on codependent submissions.
Jing Bo has a broad and deep understanding of the technical, political, and strategic aspects of the Australian reimbursement system, having worked on over 40 submissions / commentaries across multiple clinical areas in 7 years (including: oncology, immunology, asthma, infectious diseases, bowel disease, cardiology and neurology). Due to her unique profile of experience across multiple sectors of the health system and health technology assessment (HTA) pathways, she has developed extensive HTA skills, both technically and in understanding how HTA is used by government decision makers/payers.
Research area keywords
- Economic Evaluation
- Health Technology Assessments